|
Hypercholesterolemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The ACAT-2 and CYP7A1 mRNA expression were significantly decreased in HC diet supplemented with STG, while the mRNA levels of LDLR were markedly increased.
|
30937311 |
2019 |
|
Liver diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The existence of a new class of potent and selective SOAT2 inhibitors provides an opportunity for exploring if suppression of this enzyme could potentially become an adjunctive therapy for liver disease in NPC1 deficiency.
|
29878847 |
2018 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Genes associated with β-oxidation (peroxisome proliferator-activated receptor α, carnitine palmitoyltransferase 1A, and hydroxyacyl-CoA dehydrogenase), lipoprotein excretion (apolipoprotein B, microsomal triglyceride transfer protein, and acyl-CoA:cholesterol acyltransferase 2), fatty acid transport (fatty acid-binding protein), construction of triglycerides in the endoplasmic reticulum (acyl-CoA:diacylglycerol acyltransferase 1), and LD degradation/lipolysis (comparative gene identification-58, adipose triglyceride lipase) were significantly downregulated in neoplasms compared with non-tumor areas.
|
26513060 |
2016 |
|
Chronic Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
CKD also resulted in increased enzymatic activity of HMG-CoA reductase and ACAT2 together with decreased enzyme activity of lipase and LCAT.
|
31828139 |
2019 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Human acyl-CoA:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma.
|
16274362 |
2006 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Human acyl-CoA:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma.
|
16274362 |
2006 |
|
Celiac Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Celiac disease biomarkers identified by transcriptome analysis of small intestinal biopsies.
|
30097691 |
2018 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Acyl-coenzyme A:cholesterol acyltransferase-2 (ACAT-2) is responsible for elevated intestinal ACAT activity in diabetic rats.
|
15242859 |
2004 |
|
Kidney Failure, Chronic
|
0.200 |
Biomarker
|
disease |
RGD |
The CRF animals showed a significant reduction in creatinine clearance, marked hypertriglyceridemia, modest hypercholesterolemia, and significant upregulation of hepatic tissue ACAT-2 protein and mRNA abundance.
|
12217884 |
2002 |
|
Nephrotic Syndrome
|
0.200 |
Biomarker
|
group |
RGD |
Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome.
|
11967026 |
2002 |
|
Chronic kidney disease stage 5
|
0.200 |
Biomarker
|
disease |
RGD |
Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure.
|
12217884 |
2002 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Depletion of the cholesterol esterifying enzyme acyl-Coenzyme A: cholesterol acyltransferase 2 (ACAT2, encoded by Soat2) protects mice from atherosclerosis, diet-induced hypercholesterolemia, and hepatic steatosis when fed high-cholesterol diet.
|
30630736 |
2019 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice.
|
16195894 |
2005 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice.
|
16195894 |
2005 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Depletion of the cholesterol esterifying enzyme acyl-Coenzyme A: cholesterol acyltransferase 2 (ACAT2, encoded by Soat2) protects mice from atherosclerosis, diet-induced hypercholesterolemia, and hepatic steatosis when fed high-cholesterol diet.
|
30630736 |
2019 |
|
Hypercholesterolemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice.
|
16195894 |
2005 |
|
Wolman Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, these data imply that SOAT2 inhibition, if applied concurrently with enzyme replacement therapy for LAL deficiency, may blunt the re-esterification of newly released unesterified cholesterol thereby improving clinical outcomes.
|
29246491 |
2018 |
|
Wolman Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
These studies illustrate how the severity of disease in a mouse model for CESD can be substantially ameliorated by elimination of SOAT2 function.
|
25450374 |
2014 |
|
Dyslipidemias
|
0.020 |
Biomarker
|
group |
BEFREE |
These new analogues are the most potent and selective SOAT2 inhibitors to be used as synthetic compounds and attractive seed compounds for the development of drug for dyslipidemia, including atherosclerotic disease and steatosis.
|
29323466 |
2018 |
|
Dyslipidemias
|
0.020 |
Biomarker
|
group |
BEFREE |
To investigate the relationship between ACAT-2 and dyslipidemia, we determined the structure of the human ACAT-2 gene and then studied the relationship between mutations of the ACAT-2 gene and dyslipidemia.
|
11325614 |
2001 |
|
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here we aimed to investigate whether depletion of Soat2 per se can reduce hepatic steatosis, also in the presence of very low levels of cholesterol in the diet, and the underlying mechanisms.
|
30630736 |
2019 |
|
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
These new analogues are the most potent and selective SOAT2 inhibitors to be used as synthetic compounds and attractive seed compounds for the development of drug for dyslipidemia, including atherosclerotic disease and steatosis.
|
29323466 |
2018 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In mouse models, previous work has demonstrated that either antisense oligonucleotide (ASO) or small molecule inhibitors of SOAT2 can effectively reduce CVD progression, and even promote regression of established CVD.
|
26729489 |
2016 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we aimed to investigate whether depletion of Soat2 per se can reduce hepatic steatosis, also in the presence of very low levels of cholesterol in the diet, and the underlying mechanisms.
|
30630736 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Based on GO, KEGG, GenMAPP, BioCarta and disease databases, we determined AGR2-mediated lung adenocarcinoma metastasis through repression with cytoskeleton of MAST1; steroid metabolism of SOAT2; humoral immune response of POU2AF1; interferon alpha-inducible of IFI6; immunoglobulin of IGKC_3, CTA_246H3.1.
|
24960290 |
2014 |